MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib
Margaret Whicker(Yale University), Elena Ratner(Yale University)
Cited by 34
Related Papers
NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019
|Journal of the National Comprehensive Cancer Network|2019|332
Transforming Growth Factor Beta and Epithelial to Mesenchymal Transition Alter Homologous Recombination Repair Gene Expression and Sensitize BRCA Wild Type Ovarian Cancer Cells to Olaparib
|Preprints.org|2023|5
Risk‐stratifying clinicopathologic criteria for ovarian preservation in premenopausal women with early stage low‐risk endometrial cancer
|International Journal of Gynecology & Obstetrics|2020|2
The incidence of microscopic adnexal metastatic disease in women with presumed early stage endometrial cancer.
|Journal of Clinical Oncology|2019|0